Testing Drugs to Reduce Bleeding During Surgery in Kidney Patients
Tests tranexamic acid and desmopressin against placebo in adults with kidney disease having surgery.
Plain-language title generated from the registry record
Registry title: Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Key facts
- Where
- London and Montreal, CanadaSee the 3 sites
- Phase
- Phase 3
Where in Canada
- London Health Sciences CentreLondon, CanadaTaking people
- McGill University University Health CentreMontreal, CanadaTaking people
- Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hamilton Health Sciences Corporation
- Trial code
- NCT06337838
- Record updated
- 22 May 2026
- Original description
The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.Read full original descriptionShow less
Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial
The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.
Inclusion: Included in the TXA factorial.
Exclusion: Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or; Previously enrolled in the BRACKETS-Pilot Trial; Eligibility criteria specific to the desmopressin factorial component of trial; Undergoing cardiac surgery; Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access; Hypersensitivity or known allergy to TXA; History of seizure disorder; Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft; History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome; Hypersensitivity or known allergy to desmopressin; Most recent serum sodium concentration < 130 mEq/L; Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or; Undergoing intracranial neurosurgery; Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid; The hospital does not have access to desmopressin; Planned use of prophylactic desmopressin.
Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:; One of either:; 1.1. eGFR <25 ml/min/1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days; Planned noncardiac surgery (elective, urgent, or emergency surgery); Expected to require at least an overnight hospital admission after surgery; Age ≥18 years; and; Informed consent is obtained to participate in the BRACKETS-Pilot Trial.